3.68

3.08% 0.11

Galectin Therapeutics Inc (GALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Galectin Therapeutics Inc stock is traded at $3.68, with a volume of 174.89K. It is up +3.08% in the last 24 hours and down -4.29% over the past month. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Previous Close:

$3.57

Open:

$3.62

24h Volume:

174.89K

Relative Volume:

0.27

Market Cap:

$371.13M

Revenue:

Net Income/Loss:

$-26.25M

P/E Ratio:

-8.9778

EPS:

-0.4099

Net Cash Flow:

$-20.05M

1W Performance:

+6.98%

1M Performance:

-4.29%

6M Performance:

+23.91%

1Y Performance:

-5.15%

1-Day Range:

$3.5871

$3.74

1-Week Range:

$3.31

$3.77

52-Week Range:

$2.025

$7.13

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name

Galectin Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

678-620-3186

Address

4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA

Employee

Twitter

@galectingalt

Next Earnings Date

2026-08-13

Latest SEC Filings

GALT's Discussions on Twitter

Compare GALT vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GALT Galectin Therapeutics Inc	3.68	360.03M	0	-26.25M	-20.05M	-0.4099
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Resumed	H.C. Wainwright	Buy
Aug-13-20	Reiterated	H.C. Wainwright	Buy
Feb-13-19	Initiated	B. Riley FBR	Buy
Dec-07-17	Reiterated	H.C. Wainwright	Buy
Nov-28-17	Reiterated	H.C. Wainwright	Buy
Oct-19-17	Initiated	ROTH Capital	Buy
Mar-30-17	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-03-16	Downgrade	FBR & Co.	Outperform → Mkt Perform
Sep-29-16	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-28-16	Downgrade	ROTH Capital	Buy → Sell
Mar-28-16	Resumed	H.C. Wainwright	Buy
Sep-21-15	Initiated	H.C. Wainwright	Buy
Aug-01-14	Downgrade	Aegis Capital	Buy → Hold
Jul-30-14	Reiterated	MLV & Co	Buy
Jul-29-14	Reiterated	MLV & Co	Buy
Apr-02-14	Reiterated	MLV & Co	Buy
Feb-10-14	Reiterated	Aegis Capital	Buy
Jan-09-14	Reiterated	Aegis Capital	Buy
Dec-03-13	Initiated	MLV & Co	Buy
Aug-19-13	Reiterated	Aegis Capital	Buy

View All

Galectin Therapeutics Inc Stock (GALT) Latest News

Aug 20, 2026

Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available RecordUpward Estimate Revision - vinanet.vn

Aug 20, 2026

Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn

Aug 20, 2026

Aug 18, 2026

HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat

Aug 18, 2026

Aug 17, 2026

Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusSuperTrend Flip - vinanet.vn

Aug 17, 2026

Aug 15, 2026

H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Aug 15, 2026

Aug 14, 2026

Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat

Aug 14, 2026

Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade

Aug 14, 2026

Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart

Aug 14, 2026

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView

Aug 14, 2026

Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com

Aug 14, 2026

Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative

Aug 14, 2026

Galectin Therapeutics、2026年6月30日決算の結果を発表し、事業状況を更新 - Moomoo

Aug 14, 2026

GALT Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView

Aug 14, 2026

Aug 13, 2026

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat

Aug 13, 2026

Aug 10, 2026

Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 08, 2026